Liu Bin, Li Jing, Zhang Yong-Jiu, Yan Lu-Nan, You Sheng-Yi, Lau Wan-Yee, Sun Hao-Ran, Yan Shi-Yan, Wang Zhi-Qiang
Bin Liu, Zhi-Qiang Wang, Department of Critical Care Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China.
World J Gastroenterol. 2015 May 14;21(18):5488-95. doi: 10.3748/wjg.v21.i18.5488.
To investigate the outcomes of pancreas-sparing duodenectomy (PSD) with regional lymph node dissection vs pancreaticoduodenectomy (PD).
Between August 2001 and June 2014, 228 patients with early-stage ampullary carcinoma (Amp Ca) underwent surgical treatment (PD, n = 159; PSD with regional lymph node dissection, n = 69). The patients were divided into two groups: the PD group and the PSD group. Propensity scoring methods were used to select patients with similar disease statuses. A total of 138 matched cases, with 69 patients in each group, were included in the final analysis.
The median operative time was shorter among the patients in the PSD group (435 min) compared with those in the PD group (481 min, P = 0.048). The median blood loss in the PSD group was significantly less than that in the PD group. The median length of hospital stay was shorter for patients in the PSD group vs the PD group. The incidence of pancreatic fistula was higher among patients in the PD group vs the PSD group. The 1-, 3-, and 5-year overall survival and disease-free survival rates for patients in the PSD group were 83%, 70%, 44% and 73%, 61%, 39%, respectively, and these values were not different than compared with those in the PD group (P = 0.625).
PSD with regional lymph node dissection presents an acceptable morbidity in addition to its advantages over PD. PSD may be a safe and feasible alternative to PD in the treatment of early-stage Amp Ca.
探讨保留胰腺十二指肠切除术(PSD)联合区域淋巴结清扫与胰十二指肠切除术(PD)的治疗效果。
2001年8月至2014年6月期间,228例早期壶腹癌(Amp Ca)患者接受了手术治疗(PD组159例;PSD联合区域淋巴结清扫组69例)。患者分为两组:PD组和PSD组。采用倾向评分法选择疾病状态相似的患者。最终分析纳入138例匹配病例,每组69例。
PSD组患者的中位手术时间(435分钟)短于PD组(481分钟,P = 0.048)。PSD组的中位失血量明显少于PD组。PSD组患者的中位住院时间短于PD组。PD组患者的胰瘘发生率高于PSD组。PSD组患者1年、3年和5年的总生存率和无病生存率分别为83%、70%、44%和73%、61%、39%,与PD组相比无差异(P = 0.625)。
PSD联合区域淋巴结清扫除了优于PD外,还具有可接受的发病率。在早期Amp Ca的治疗中,PSD可能是PD的一种安全可行的替代方案。